The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...
Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...
We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...
We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...
Which biotechs are most likely to be acquired near-term? We asked Seeking Alpha analysts Edmund Ingham and Terry Chrisomalis for their thoughts on the topic. Read more here.